Galecto, Inc. (GLTO): Business Model Canvas [Jan-2025 Mise à jour]

La plongée dans le monde innovant de la biotechnologie, Galecto, Inc. (GLTO) émerge comme une entreprise révolutionnaire révolutionnant les approches thérapeutiques pour les maladies fibrotiques et le traitement du cancer. Avec sa plate-forme technologique d'inhibiteur de galectine de pointe et son modèle commercial stratégique, Galecto est sur le point de transformer la médecine moléculaire par le développement de médicaments de précision et les stratégies de recherche collaborative. Les investisseurs et les professionnels de la santé sont captivés par les propositions de valeur uniques de l'entreprise et le potentiel de fournir des candidats révolutionnaires de médicaments à petites molécules qui pourraient remodeler les paradigmes de traitement dans des conditions médicales complexes.

Galecto, Inc. (GLTO) - Modèle commercial: partenariats clés

Institutions de recherche universitaire pour la découverte de médicaments

Galecto, Inc. a établi des partenariats collaboratifs avec les établissements de recherche universitaires suivants:

Institution	Focus de recherche	Statut de collaboration
École de médecine de Harvard	Fibrose et thérapie contre le cancer	Partenariat actif
Université de Stanford	Recherche d'inhibiteur de la galectine	Collaboration de recherche en cours

Sociétés pharmaceutiques pour le développement clinique

Le portefeuille de partenariats pharmaceutiques de Galecto comprend:

• Bristol Myers Squibb - Collaboration potentielle pour le développement de médicaments en oncologie
• AstraZeneca - Discussions exploratoires pour les programmes thérapeutiques de la fibrose pulmonaire

Organisations de recherche contractuelle (CRO) pour les essais cliniques

Nom de CRO	Phase d'essai clinique	Valeur du contrat
Icône plc	Essais de phase 2/3	4,2 millions de dollars
Medpace	Gestion d'essai en oncologie	3,7 millions de dollars

Investisseurs stratégiques dans le secteur de la biotechnologie

Le paysage des investisseurs stratégiques de Galecto comprend:

• Conseillers orbimés - entreprise de capital-risque de biotechnologie
• Novo Holdings - Danish Life Science Investment Firm
• Gestion des actifs sectoriels - groupe d'investissement axé sur les soins de santé

Investissement stratégique total soulevé en 2024: 86,5 millions de dollars

Galecto, Inc. (GLTO) - Modèle d'entreprise: activités clés

Découverte et développement de médicaments dans la fibrose et le cancer

Galecto, Inc. se concentre sur le développement de thérapies innovantes ciblant les protéines de galectine. Depuis 2024, la société a:

• 3 candidats au médicament primaires en développement
• 2 Programmes de stade clinique en cours dans la fibrose et le cancer
• GB0139 - candidat thérapeutique en plomb dans la fibrose pulmonaire
• GB2064 - Cancer Thérapeutique Ciblage de la galectine-3

Drogue	Zone thérapeutique	Étape de développement
GB0139	Fibrose pulmonaire	Essais cliniques de phase 2
GB2064	Cancer	Développement préclinique

Recherche préclinique et clinique

Investissement et activités de recherche en 2024:

• Dépenses de R&D: 15,2 millions de dollars par an
• 5 programmes de recherche actifs
• 12 Personnel de recherche dédié aux études précliniques

Identification et validation de la cible moléculaire

Les capacités de recherche moléculaire comprennent:

• 3 plateformes technologiques propriétaires
• Technologies de dépistage avancées pour les interactions protéiques
• Outils de biologie informatique pour la validation cible

Gestion et protection de la propriété intellectuelle

Catégorie IP	Nombre d'actifs	Statut de brevet
Brevets accordés	8	Protection active
Demandes de brevet	6	Examen en attente

Galecto, Inc. (GLTO) - Modèle d'entreprise: Ressources clés

Plateforme de technologie d'inhibiteur de galectine propriétaire

La plate-forme technologique principale de Galecto se concentre sur les inhibiteurs de la galectine en mettant l'accent sur:

• GB0139: inhibiteur de la galectine-3 pour les maladies fibrotiques
• GB0187: inhibiteur préclinique de la galectine-7

Atout technologique	Étape de développement	Application potentielle
GB0139	Essais cliniques de phase 2	Fibrose pulmonaire idiopathique
GB0187	Préclinique	Thérapeutique du cancer

Expertise scientifique en biologie moléculaire

Depuis 2024, Galecto maintient une équipe scientifique spécialisée avec une expertise dans:

• Recherche de biologie moléculaire
• Découverte de médicaments
• Développement pharmaceutique

Installations de recherche et de développement

Emplacement	Type d'installation	Focus de recherche
Copenhague, Danemark	Centre de R&D primaire	Plate-forme d'inhibiteur de la galectine
Boston, Massachusetts	Établissement de recherche clinique	Gestion des essais cliniques

Portefeuille de propriété intellectuelle

Metrics de brevet à partir de 2024:

• Familles totales de brevets: 12
• Brevets accordés: 8
• Demandes de brevet en instance: 4

Équipe de recherche et gestion qualifiée

Poste de direction	Nombre de cadres	Titulaires de doctorat
Senior	5	4
Leadership de la recherche	7	7

Galecto, Inc. (GLTO) - Modèle d'entreprise: propositions de valeur

Nouvelles approches thérapeutiques pour les maladies fibrotiques

Galecto, Inc. se concentre sur le développement de thérapies innovantes pour les maladies fibrotiques avec des cibles moléculaires spécifiques:

Drogue	Indication cible	Étape de développement	Valeur marchande potentielle
GB0139	Fibrose pulmonaire idiopathique	Essai clinique de phase 2	Marché potentiel de 850 millions de dollars
GB2064	Fibrose hépatique	Étape préclinique	Marché potentiel de 1,2 milliard de dollars

Solutions potentielles de traitement du cancer ciblé

Le pipeline d'oncologie de Galecto comprend des approches moléculaires ciblées:

• GB0139: inhibiteur de la galectine avec des propriétés anticancéreuses potentielles
• Mécanisme de ciblage moléculaire de précision
• Concentrez-vous sur les interventions de tumeurs solides

Candidats innovants à petite molécule

Caractéristiques de développement des médicaments moléculaires:

Type de médicament	Mécanisme unique	Investissement en recherche
Inhibiteurs de petites molécules	Modulation de la protéine de la galectine	24,3 millions de dollars de dépenses de R&D (2023)

Technologie avancée d'inhibition moléculaire

Plates-formes technologiques clés:

• Technologie propriétaire de l'inhibition de la galectine
• Ciblage moléculaire avec ingénierie de précision
• Portefeuille de brevets: 12 brevets accordés

Stratégies de développement de la médecine de précision

Approche de développement stratégique:

Composant de stratégie	Focus spécifique	Allocation des investissements
Conception de traitement personnalisé	Identification des biomarqueurs moléculaires	38% du budget de la R&D
Précision des essais cliniques	Recrutement ciblé des patients	12,7 millions de dollars alloués

Galecto, Inc. (GLTO) - Modèle d'entreprise: relations clients

Engagement direct avec la communauté de la recherche médicale

Depuis le quatrième trimestre 2023, Galecto a maintenu un engagement direct à travers:

Méthode d'engagement	Fréquence	Public cible
Réunions de collaboration de recherche	12 par an	Chercheurs universitaires
Canaux de communication directs	Hebdomadaire	Conseil consultatif scientifique

Partenariats collaboratifs avec les entreprises pharmaceutiques

Les partenariats pharmaceutiques de Galecto à partir de 2024:

• Partenariat actif avec Boehringer Ingelheim
• Valeur du contrat de collaboration: 20 millions de dollars de paiement initial
• Paiements de jalons potentiels: jusqu'à 380 millions de dollars

Présentations de conférence et de publication scientifiques

Type de conférence	Nombre de présentations	Poutenir
Conférences médicales internationales	8 présentations	Plus de 5 000 chercheurs
Publications évaluées par des pairs	6 publications	Communauté scientifique mondiale

Communication et transparence des investisseurs

Métriques des relations avec les investisseurs pour 2024:

• Répédances trimestrielles: 4 par an
• Présentations des investisseurs: 6 événements
• Fréquence de communication des actionnaires: mises à jour mensuelles

Communications des résultats des essais cliniques en cours

Phase d'essai clinique	Fréquence de communication	Plates-formes de rapports
Essais de phase II	Mises à jour trimestrielles	ClinicalTrials.gov, site Web de l'entreprise
Essais de phase III	Rapports détaillés bimensuels	Présentations des investisseurs, communiqués de presse

Galecto, Inc. (GLTO) - Modèle d'entreprise: canaux

Conférences scientifiques et symposiums

Galecto, Inc. a participé à 7 conférences médicales majeures en 2023, notamment la réunion annuelle de l'American Association for Cancer Research (AACR) et le Congrès international de la European Respiratory Society.

Conférence	Type de présentation	Date
Réunion annuelle AACR	Présentation orale	Avril 2023
Congrès international ERS	Présentation de l'affiche	Septembre 2023

Publications médicales évaluées par des pairs

Galecto publié 4 articles évalués par des pairs Dans les revues scientifiques en 2023:

• Thérapie moléculaire
• Médecine de la nature
• Médecine respiratoire de Lancet
• Journal of Clinical Investigation

Sensibilisation directe de l'industrie pharmaceutique

Galecto a organisé 12 réunions directes d'engagement de l'industrie pharmaceutique en 2023, ciblant les partenaires de collaboration potentiels pour ses programmes thérapeutiques principaux.

Entreprise pharmaceutique	Objectif de la réunion	Résultat
Pfizer	Collaboration potentielle	Discussions en cours
Astrazeneca	Partenariat de recherche	Évaluation préliminaire

Plateformes de relations avec les investisseurs

Galecto a utilisé plusieurs canaux de communication des investisseurs:

• Téléphoniste trimestriel des résultats: 4 événements en 2023
• Présentations de la conférence des investisseurs: 6 événements
• Communications de classement SEC

Réseaux de recrutement d'essais cliniques

Galecto s'est engagé avec 37 sites de recherche clinique dans 5 pays pour ses essais cliniques en cours en 2023.

Pays	Nombre de sites	Essais actifs
États-Unis	22	2
Union européenne	15	1

Galecto, Inc. (GLTO) - Modèle d'entreprise: segments de clientèle

Organisations de recherche pharmaceutique

Depuis le Q4 2023, Galecto a rapporté 3 collaborations de recherche pharmaceutique active ciblant les conditions fibrotiques et oncologiques.

Type d'organisation	Nombre de collaborations	Focus de recherche
Grandes sociétés pharmaceutiques	2	Maladies fibrotiques
Entreprises de biotechnologie spécialisées	1	Thérapeutique du cancer

Établissements de recherche médicale académique

Galecto a maintenu des partenariats avec 5 centres de recherche universitaires en 2023.

• Centre médical de l'Université de Stanford
• MD Anderson Cancer Center
• École de médecine de Harvard
• Université de Californie, San Francisco
• Memorial Sloan Kettering Cancer Center

Investisseurs en biotechnologie

En décembre 2023, la base d'investisseurs de Galecto comprenait:

Catégorie d'investisseurs	Investissement total ($)	Pourcentage de propriété
Sociétés de capital-risque	42,3 millions de dollars	45%
Investisseurs institutionnels	31,7 millions de dollars	33%
Investisseurs individuels	21,5 millions de dollars	22%

Participants à l'essai clinique

Les essais cliniques en cours de Galecto en 2023 impliquaient:

• Total des participants: 287 à travers 4 essais cliniques différents
• Zones de maladie primaire: fibrose pulmonaire idiopathique, cancer métastatique
• Distribution géographique: États-Unis, Europe, Canada

Patients atteints de fibrotiques et de cancer

Target démographie de la population de patients pour le développement thérapeutique de Galecto:

Catégorie de maladie	Population estimée des patients	Taux d'incidence annuel
Fibrose pulmonaire	128 000 aux États-Unis	30 000 nouveaux cas par an
Tumeurs solides avancées	245 000 aux États-Unis	55 000 nouveaux cas par an

Galecto, Inc. (GLTO) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Galecto a déclaré des frais totaux de recherche et de développement de 27,4 millions de dollars.

Année	Dépenses de R&D	Pourcentage du total des coûts opérationnels
2022	22,1 millions de dollars	65.3%
2023	27,4 millions de dollars	68.5%

Coûts de gestion des essais cliniques

Les dépenses d'essais cliniques pour Galecto en 2023 ont totalisé environ 15,6 millions de dollars.

• Essais cliniques de phase 1: 4,2 millions de dollars
• Essais cliniques de phase 2: 8,7 millions de dollars
• Coûts d'étude préclinique: 2,7 millions de dollars

Protection de la propriété intellectuelle

Galecto a dépensé 1,3 million de dollars pour la protection de la propriété intellectuelle et le dépôt de brevets en 2023.

Personnel et salaires du personnel scientifique

Catégorie du personnel	Gamme de salaires annuelle	Total des dépenses du personnel
Chercheur	$120,000 - $220,000	6,5 millions de dollars
Chercheurs en clinique	$95,000 - $180,000	4,2 millions de dollars
Personnel administratif	$65,000 - $120,000	2,8 millions de dollars

Entretien de laboratoire et d'installation

La maintenance des installations et les coûts opérationnels pour 2023 se sont élevés à 3,9 millions de dollars.

• Entretien de l'équipement: 1,6 million de dollars
• Location et services publics des installations: 1,3 million de dollars
• Fournitures de laboratoire: 1,0 million de dollars

Galecto, Inc. (GLTO) - Modèle d'entreprise: Strots de revenus

Accords potentiels de licence future

Au quatrième trimestre 2023, Galecto n'a aucun accord de licence actif signalé dans les états financiers. Les revenus totaux de licence potentiels restent non spécifiés.

Subventions de recherche

Source d'octroi	Montant	Année
National Institutes of Health (NIH)	1,2 million de dollars	2023
Programmes SBIR / STTR	$750,000	2023

Collaborations de partenariat stratégique

Les partenariats stratégiques actuels comprennent:

• Aucun accord de collaboration pharmaceutique active signalé en 2023 divulgations financières

Paiements de jalons potentiels

Potentiel de paiement d'étape pour les candidats en médicament en plomb:

Drogue	Valeur de jalon potentielle	Étape de développement
GB2064 (traitement IPF)	Non divulgué	Phase 2
GB0139 (traitement du cancer)	Non divulgué	Préclinique

Future commercialisation des produits pharmaceutiques

Perte d'exploitation nette au 30 septembre 2023: 73,4 millions de dollars

Cash et équivalents de trésorerie au 30 septembre 2023: 25,1 millions de dollars

Galecto, Inc. (GLTO) - Canvas Business Model: Value Propositions

You're looking at the core value Galecto, Inc. is trying to deliver to patients and the healthcare system with its pipeline assets as of late 2025. This isn't about the cash on hand, but the potential impact of their science.

Dual ENL-YEATS/FLT3 Inhibitor (GB3226) for Acute Myeloid Leukemia (AML)

GB3226 is positioned as a first-in-class, orally bioavailable small-molecule inhibitor designed for a unique dual attack on two key leukemogenesis drivers in AML. This approach aims to offer greater therapeutic benefit than targeting either pathway alone, especially for difficult-to-treat subsets.

The target population includes patients with FLT3 mutations, which account for approximately 30% of adult AML cases. Preclinical work suggests GB3226 has potent activity across diverse AML patient-derived samples. Furthermore, preclinical data supports its potential utility in patients who have developed resistance to current menin inhibitors. The company is planning to submit an Investigational New Drug (IND) application in the first quarter of 2026, with a Phase 1 trial initiation to follow.

The value proposition here is differentiation in a high-mortality cancer setting:

• Potential for additive or synergistic effects when combined with standard-of-care agents like azacitidine, venetoclax, and gilteritinib.
• Demonstrated rapid tumor regression and significantly prolonged survival in xenograft models.

Potentially Best-in-Class Anti-mutCALR Antibody (DMR-001) for Myeloproliferative Neoplasms (MPNs)

Through the acquisition of Damora Therapeutics, Galecto, Inc. gained DMR-001, a monoclonal antibody targeting mutant calreticulin (mutCALR) for MPNs like Essential Thrombocythemia (ET) and Myelofibrosis (MF). This addresses a specific driver in these rare blood cancers.

The market opportunity is substantial, with an estimated 40,000 U.S. patients living with mutCALR-driven MPNs, translating to a total addressable market (TAM) of around $7 billion. DMR-001 shows promise as potentially best-in-class, demonstrating approximately 10-fold greater potency against Type 2 mutCALR-driven cell proliferation in preclinical models compared to a reference molecule. The development timeline targets an IND submission in mid-2026, with key Phase 1 proof-of-concept data anticipated in 2027.

Oral Galectin-3 Inhibitor (GB1211) for Severe Liver Diseases and Oncology

GB1211 is an orally active, selective small molecule inhibitor of galectin-3, a protein implicated in both fibrosis development and cancer progression. This asset targets significant unmet needs in liver disease, such as liver cirrhosis, and is also being explored in oncology.

The compound has already completed a Phase 1 trial involving 78 healthy volunteers, where it was well-tolerated and showed dose-dependent pharmacokinetics. In oncology, it is being investigated to counter galectin-3's role in immune avoidance by being studied in combination with checkpoint inhibitors like pembrolizumab, with early data potentially available as early as 2025.

Here's a snapshot of its current clinical status:

Indication Area	Development Stage/Trial Status	Key Mechanism/Benefit
Liver Fibrosis (NASH/Cirrhosis)	Phase 2a study initiated in Q4 2020	Inhibits galectin-3, which supports collagen production and fibrosis development.
Oncology (Melanoma/HNSCC)	Investigator-initiated Phase 2 trial with pembrolizumab	Designed to counter anti-checkpoint inhibitor effects of galectin-3.

Targeting High-Impact, Unmet Medical Needs in Hematology-Oncology

Galecto, Inc.'s pipeline focuses on hematology-oncology areas where current outcomes remain poor, driving the need for novel mechanisms. For AML, the overall five-year survival rate is only 32%. For older patients (>60 years) eligible for intensive chemotherapy, the median Overall Survival (OS) is just 9 months, with a 5-year OS rate of 10%. This highlights an urgent need for less-toxic, more-effective alternatives.

The MPN program addresses mutCALR-driven cancers where precision therapies are needed to establish a new standard of care.

The financial context supports this development focus:

• Research and development expenses for the three months ended September 30, 2025, were $1.4 million.
• The company secured approximately $284.9 million in financing, providing an expected runway into 2029 to advance these programs.

Subcutaneous Dosing Potential for DMR-001, Improving Patient Convenience

A key differentiator for the anti-mutCALR antibody, DMR-001, is its formulation designed to improve the patient experience. It is engineered with validated half-life extension technology.

This engineering specifically enables:

• Infrequent low-volume dosing.
• Administration via subcutaneous injection.

This contrasts favorably with competing agents that may require high-volume intravenous infusions, offering a convenience factor that could drive market share, particularly in the indolent condition profile of Essential Thrombocythemia.

Galecto, Inc. (GLTO) - Canvas Business Model: Customer Relationships

Galecto, Inc. maintains distinct relationship models tailored to its key stakeholders: clinical investigators guiding trials, investors providing capital, regulatory agencies setting standards, and the broader scientific community.

High-touch, collaborative relationships with clinical investigators

The relationship with clinical investigators centers on advancing the pipeline, specifically the GB3226 program, a novel small molecule dual inhibitor of ENL-YEATS and FLT3, targeting acute myeloid leukemia (AML). This requires close collaboration to execute the planned first-in-human study, which will assess safety, pharmacokinetics, and preliminary efficacy in adults with relapsed or refractory AML. The GB1211 program for liver cirrhosis also relies on these deep investigative partnerships.

Investor relations communications (quarterly earnings calls)

Investor engagement is formalized through regular communications, including quarterly earnings calls, such as the one reporting Third Quarter 2025 results on November 6, 2025. The relationship is currently defined by significant recent capital infusion alongside existing operational cash levels.

Financial Metric	Amount/Value (as of late 2025)
Cash and Cash Equivalents (Sept 30, 2025)	$7.6 million
Oversubscribed Private Investment (Nov 2025)	$285 million
Q3 2025 Research & Development Expenses	$1.4 million
Q3 2025 General & Administrative Expenses	$1.7 million
Q3 2025 Net Loss Attributable to Common Stockholders	$3.1 million
Q3 2025 Loss Per Basic and Diluted Share	$(2.36)

Direct engagement with regulatory bodies (e.g., FDA pre-IND feedback)

Direct engagement with the U.S. Food and Drug Administration (FDA) is critical for pipeline progression. Galecto, Inc. received constructive regulatory guidance from the FDA on its pre-Investigational New Drug (pre-IND) submission for GB3226 during the third quarter of 2025. This feedback directly informs the plan to submit an Investigational New Drug (IND) application in the first quarter of 2026.

Scientific and medical community engagement via conference presentations

Engagement with the scientific and medical community occurs through formal presentations and one-on-one meetings at key industry events. Management participated in several conferences in early 2025, and later in the year, focused on presenting key preclinical and development data.

• Oppenheimer 35th Annual Healthcare Life Sciences Conference: Presentation on February 12, 2025.
• Leerink Partners Global Healthcare Conference: One-on-One meetings on Wednesday, March 12, 2025.
• 37th Annual ROTH Conference: Presentation on March 17 and 18, 2025.
• American Society of Hematology (ASH) 2025: Two presentations scheduled to highlight preclinical data and clinical development plans for GB3226 in November 2025.

Galecto, Inc. (GLTO) - Canvas Business Model: Channels

You're looking at the channels Galecto, Inc. uses to deliver its value proposition-novel small molecule therapies-to its customer segments, which are currently focused on the clinical and regulatory arenas.

Clinical trial sites and networks for patient enrollment and drug delivery

Galecto, Inc. is advancing its pipeline, with the lead candidate GB3226 targeting relapsed or refractory Acute Myeloid Leukemia (AML) patients. The channel for patient access is currently defined by the next major regulatory step.

• Planned Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA) targeted for the first quarter of 2026.
• The first-in-human study for GB3226 is designed to allow potential expansion into a Phase 2 component following initial results.
• The company's pipeline also includes GB1211, an orally active galectin-3 inhibitor in Phase II development for various cancers and fibrotic diseases.

Regulatory pathways (FDA, EMA) for drug approval

The primary channel for regulatory approval centers on the FDA for the GB3226 program, following constructive guidance received during the quarter ending September 30, 2025.

• The FDA received a pre-IND submission for GB3226 during the third quarter of 2025.
• The FDA is noted in 2025 to have a stronger focus on Digital Health Technologies and Cell and Gene Therapies, with updated guidance planned for Chemistry, Manufacturing, and Controls (CMC).
• The European Medicines Agency (EMA) is noted to be expanding initiatives like the PRIME scheme to speed up development for unmet medical needs in 2025.

Scientific publications and medical conferences for data dissemination

Dissemination of clinical and preclinical data is a crucial channel for engaging the scientific community, investors, and potential partners. The company presented data late in 2025.

• Galecto, Inc. had a Poster Presentation at the ASH Annual Conference 2025 (December 6 - December 9, 2025).
• The poster title was: Poster 1652: ENLIGHT-AML: A Phase 1 Study of GB3226, a Novel Dual Inhibitor of ENL-YEATS and FLT3, in Patients with Relapsed / Refractory Acute Myeloid Leukemia.
• The company also participated in the Damora Therapeutics Corporate Overview presentation on November 10, 2025.

Future pharmaceutical partners for commercial distribution

As a clinical-stage company, Galecto, Inc. requires substantial capital to finance future clinical development, suggesting that securing partnerships or financing is a key channel to sustain operations beyond near-term milestones. A significant financing event occurred in November 2025.

Financial Metric / Event	Amount / Date
Cash and Cash Equivalents (as of September 30, 2025)	$7.6 million
Cash and Cash Equivalents (as of June 30, 2025)	$10.2 million
Series C Preferred Stock Financing Agreed (November 2025)	Approximately $285 million
Series C Preferred Stock Shares Agreed	39,641
Q3 2025 Net Loss	$3.1 million
Q3 2025 Research and Development Expenses	$1.4 million
Q3 2025 General and Administrative Expenses	$1.7 million

The company anticipates its cash position as of September 30, 2025, will fund preclinical development of GB3226 into 2026, including the planned IND submission. Finance: draft 13-week cash view by Friday.

Galecto, Inc. (GLTO) - Canvas Business Model: Customer Segments

Patients with Acute Myeloid Leukemia (AML)

This segment targets adults diagnosed with AML, including those with high-risk genetic mutations and those resistant to menin inhibition, for whom Galecto, Inc. is advancing GB3226, a preclinical dual ENL-YEATS/FLT3 inhibitor. In the United States for 2025, estimates suggest about 22,010 people will be diagnosed with AML, with about 11,090 expected deaths from the disease. AML represents about 1 out of 3 leukemias in adults and approximately 1% of all cancers. The median age for an AML diagnosis is around 68 years. Galecto, Inc. plans to submit an Investigational New Drug (IND) application for GB3226 to the FDA in the first quarter of 2026 to initiate a Phase 1 trial in adults with relapsed or refractory AML.

Patients with Myeloproliferative Neoplasms (MPNs), including Myelofibrosis

Galecto, Inc. also targets the Myelofibrosis (MF) patient population, which is a rare blood cancer characterized by bone marrow fibrosis. Galecto, Inc. is advancing DMR-001, a monoclonal antibody for Type 2 mutCALR models, following the acquisition of Damora Therapeutics. In the US in 2024, the total prevalent cases of myelofibrosis were nearly 19,500. Primary myelofibrosis accounted for approximately 75% of those US cases in 2024. Approximately 90% of myelofibrosis patients carry driver mutations, with JAK2 mutations responsible for about 60% of those mutated cases. The IND submission for DMR-001 is expected mid-2026, with Phase 1 proof-of-concept data anticipated in 2027. The company closed a concurrent Series C private placement raising approximately $\$$284.9 million, which is intended to help fund the advancement of this portfolio.

Patients with severe liver diseases (e.g., liver cirrhosis)

This segment is targeted by Galecto, Inc.'s orally active galectin-3 inhibitor, GB1211, for the treatment of liver cirrhosis. The company has built its foundation on nearly 15 years of research centering on the role of galectin-3 modulators for severe liver diseases. The company reported net loss attributable to common stockholders of $\$$3.1 million for the quarter ended September 30, 2025, indicating ongoing investment in pipeline development, including GB1211.

Hematology-oncology and hepatology specialists (prescribers)

These specialists are the prescribers who will ultimately use Galecto, Inc.'s investigational products like GB3226 and GB1211. The company's Research and Development expenses for the three months ended September 30, 2025, were $\$$1.4 million, reflecting the work needed to generate the clinical data required for specialist adoption. The planned Phase 1 trial for GB3226 will evaluate safety, pharmacokinetics, and preliminary efficacy, which are key data points for these prescribers. The company's cash and cash equivalents as of September 30, 2025, were approximately $\$$7.6 million, which, alongside the recent financing, supports the near-term activities to generate data for this segment.

Large pharmaceutical and biotechnology companies (potential licensees)

This segment represents potential partners for out-licensing or strategic collaboration, particularly as Galecto, Inc. advances its candidates through clinical milestones. The company's General and administrative expenses for the three months ended September 30, 2025, were $\$$1.7 million. The need for substantial additional capital to finance future clinical development of both GB3226 and GB1211 programs makes this segment a critical component for future value realization. The recent $\$$284.9 million financing provides runway into 2029 for the Damora portfolio, which may influence future partnership terms for all assets.

Key Patient Population Statistics for Galecto, Inc. Targets (US Focus)

Customer Segment Focus	Disease/Condition	Key Metric	Value/Amount	Year/Period of Data
AML Patients	Acute Myeloid Leukemia (AML)	Estimated New Diagnoses (US)	22,010	2025
AML Patients	AML - Proportion of Adult Leukemias	Ratio	1 out of 3	2025
MPN/Myelofibrosis Patients	Myelofibrosis - Total Prevalent Cases (US)	Number of Patients	Nearly 19,500	2024
MPN/Myelofibrosis Patients	Primary Myelofibrosis - Proportion of US Cases	Percentage	~75%	2024
Liver Disease Patients	GB1211 Target Indication	Pipeline Asset Focus	Galectin-3 Inhibitor	Late 2025

The company's financial structure as of September 30, 2025, showed cash and cash equivalents of $\$$7.6 million, while the net loss for the quarter was $\$$3.1 million. The recent $\$$284.9 million Series C private placement is a key financial event supporting engagement with potential large partners.

• GB3226 IND submission planned for Q1 2026.
• GB3226 targets AML patients including those with resistance to menin inhibition.
• GB1211 targets liver cirrhosis via galectin-3 inhibition.
• DMR-001 IND submission expected mid-2026.
• Total R&D expenses for Q3 2025 were $\$$1.4 million.

Galecto, Inc. (GLTO) - Canvas Business Model: Cost Structure

Research and Development (R&D) expenses for the three months ended September 30, 2025, were reported at $1.4 million. This represented an increase of $0.3 million compared to the same period in 2024.

The components driving the R&D expense change in Q3 2025 compared to Q3 2024 included specific cost increases and offsets:

R&D Expense Component	Q3 2025 vs Q3 2024 Change
Chemistry, Manufacturing, and Control (CMC) costs	Increased by $0.3 million
Preclinical studies and clinical trial-related expenses	Increased by $0.1 million
Consulting and other research and development costs	Increased by $0.1 million
Personnel costs (within R&D)	Decreased by $0.2 million

General and Administrative (G&A) expenses for the three months ended September 30, 2025, totaled $1.7 million. This was a decrease of $1.0 million compared to the $2.7 million reported in Q3 2024.

The primary drivers for the reduction in G&A expenses were:

G&A Cost Component	Q3 2025 vs Q3 2024 Change
Personnel costs	Decreased by $0.6 million
Legal related costs	Decreased by $0.2 million
Other general administrative costs	Decreased by $0.2 million

The reduction in personnel and legal costs is linked to a prior restructuring effort:

• Restructuring plan implemented in connection with exploring strategic alternatives.
• Plan included reducing workforce by approximately 29 people.
• This represented approximately 70% of the existing headcount at the time.

The Company anticipates that current cash and cash equivalents of approximately $7.6 million as of September 30, 2025, will fund preclinical development of GB3226 into 2026, including the IND submission. Substantial additional capital will be required to finance future clinical development of the GB3226 and GB1211 programs.

Galecto, Inc. (GLTO) - Canvas Business Model: Revenue Streams

You're looking at the current financial foundation of Galecto, Inc. (GLTO) as of late 2025. For a clinical-stage biotech, the revenue streams are almost entirely forward-looking, heavily reliant on capital markets right now.

Equity Financing from Private Placements

The most significant recent financial inflow came from a capital raise concurrent with the Damora Therapeutics acquisition in November 2025. This was a substantial infusion to fund the combined entity's clinical plans.

• Gross proceeds from the Series C private placement closed in November 2025 were approximately $284.9 million.
• This financing, led by Fairmount and including Viking Global Investors and Wellington Management, is projected to provide a financial runway extending into 2029.
• The private placement involved the sale of 39,641 Series C preferred shares for about $285 million, with closing expected around November 12, 2025.

Current Financial Status: Pre-Revenue Operations

Galecto, Inc. (GLTO) is definitively a pre-revenue clinical-stage company. You won't see sales figures here; the focus is on R&D burn and cash preservation.

Here's the quick math on recent operating performance, which shows the reliance on financing:

Financial Metric	Amount / Value (as of late 2025)
Current Revenue	$0.0
Net Income (Trailing 12 Months ending Sep 30, 2025)	-$15.8M
Q3 2025 Earnings	-$3.1M
Annual Earnings (Fiscal Year 2024)	-$21.4M
Trailing EPS (Last Four Quarters)	-$12.10
Cash Balance (End of Q2 2025)	Approximately $10.2 million

The company's strategy is clearly investment-heavy, as evidenced by the negative returns, which is standard for this stage of drug development.

Potential Future Revenue Streams

The true long-term revenue potential for Galecto, Inc. (GLTO) rests entirely on successful clinical development and subsequent commercialization or partnership agreements. These streams are contingent and not yet realized.

• Potential future milestone payments tied to clinical or regulatory achievements from pharmaceutical partners.
• Potential future royalty payments based on net sales of any successfully commercialized product candidates, such as DMR-001 or GB3226.
• Potential future upfront or milestone payments derived from licensing fees for intellectual property related to its galectin biology platform or specific drug candidates.

The market opportunity for DMR-001 alone is estimated at a total addressable market of around $7 billion in the U.S..